➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Moodys
Mallinckrodt
Express Scripts
Baxter

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLIMARA PRO

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

505(b)(2) Clinical Trials for Climara Pro

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00649896 ↗ Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara┬« Transdermal System 0.025 mg/Day Completed Mylan Pharmaceuticals Phase 1 2003-08-01 The primary objective of this study was to compare the adhesive quality of a new formulation of the Mylan Estradiol Transdermal System with that of Climara┬« Transdermal System following a single system application in 80 healthy postmenopausal female volunteers. As a secondary objective, primary dermal irritation was assessed after removal of each transdermal system.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Climara Pro

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Albert Einstein College of Medicine of Yeshiva University Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Brigham and Women's Hospital Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Columbia University Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Mayo Clinic Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status University of California, San Francisco Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status University of Utah Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status University of Washington Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Climara Pro

Condition Name

Condition Name for Climara Pro
Intervention Trials
Suicidal Ideation 3
Hormonal Cycling 1
Sleep Initiation and Maintenance Disorders 1
Bleeding 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Climara Pro
Intervention Trials
Suicidal Ideation 3
Depressive Disorder 2
Depression 2
Suicide 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Climara Pro

Trials by Country

Trials by Country for Climara Pro
Location Trials
United States 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Climara Pro
Location Trials
New York 4
Illinois 2
Massachusetts 2
Missouri 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Climara Pro

Clinical Trial Phase

Clinical Trial Phase for Climara Pro
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Climara Pro
Clinical Trial Phase Trials
Completed 9
Not yet recruiting 2
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Climara Pro

Sponsor Name

Sponsor Name for Climara Pro
Sponsor Trials
National Institute of Mental Health (NIMH) 3
University of Illinois at Chicago 2
Mayo Clinic 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Climara Pro
Sponsor Trials
Other 22
NIH 4
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Express Scripts
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.